此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Aortic Arch Related Cerebral Hazard Trial (ARCH) (ARCH)

2012年7月6日 更新者:Assistance Publique - Hôpitaux de Paris

Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery

The ARCH is a controlled trial with a sequential design and with a prospective, randomized, open-label, blinded-endpoint (PROBE) methodology. The objective is to compare the efficacy and tolerance (net benefit) of two antithrombotic strategies in patients with atherothrombosis of the aortic arch and a recent (less than 6 months) cerebral or peripheral embolic event.

Hypothesis:

The association of clopidogrel 75 mg/d plus aspirin 75 mg/d is 25% more effective than an oral anticoagulant (target International Normalized Ratio [INR] 2 to 3) in preventing brain infarction, brain hemorrhage, myocardial infarction, peripheral embolism, and vascular death.

研究概览

详细说明

Patients with Transient Ischemic attack or brain infarction of unknown cause (no ipsilateral internal carotid artery origin stenosis greater than 70%, no ipsilateral severe intracranial stenosis of an artery supplying the infarcted area, no definite cardiac source of embolism) in the preceding 6 months and atherosclerotic plaques.

≥ 4 mm in the aortic arch, or patients with a peripheral event (e.g. renal infarct) in the preceding 6 months and plaque ≥ 4 mm in the thoracic aorta above the origin of the embolized artery.

研究类型

介入性

注册 (实际的)

350

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Paris、法国、75018
        • Bichat Hospital Head of Neurology Department
      • Heidelberg Heights、澳大利亚、Vic 3081
        • National Stroke Research Institute-Austin Health

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

Patients of both sexes aged ≥ 18 years with the following 4 inclusion criteria:

  • One of the 3 following ischemic events in the preceding 6 months:

    • Transient ischemic attack (TIA)
    • Non-disabling brain infarcts:

      • Inclusion within 6 months after onset
      • Duration of symptoms and signs greater than 24 hours
      • Neurological signs at the time of randomization with a Rankin Scale grade 3 or less
      • With normal computed tomography (CT) scan or CT scan showing a brain infarct (even hemorrhagic infarct)
    • Peripheral embolism
  • Atherosclerotic plaque in the thoracic aorta is defined as wall thickness ≥ 4 mm where the protruding material is the largest, measured at transesophageal echocardiography with multiplane transducer or a plaque less than 4 mm but with mobile component.
  • Informed consent signed
  • Life expectancy > 3 years

Exclusion Criteria:

  • Other causes of embolism:

    • Cardiac: endocarditis, atrial fibrillation, intra-cardiac thrombus, valvular prosthesis, rheumatic valvulopathy, left ventricular aneurysm, or ejection fraction less than 25%
    • Atherosclerotic stenosis ipsilateral to the embolic territory: internal carotid artery stenosis greater than 70%, or severe (judgment of the investigator) intracranial stenosis, or scheduled carotid endarterectomy (in that case inclusion is possible 30 days after the procedure)
    • Uncommon causes: dissection, vasculitis, procoagulant state, or sickle cell disease
  • Other exclusion criteria:

    • Intercurrent illness with life expectancy less than 36 months
    • Pregnancy and non-menopausal women
    • Unwillingness to participate
    • Poor medication compliance expected
    • Toxicomania
    • Absolute indication for anticoagulant therapy (e.g. atrial fibrillation, intracardiac thrombus, prosthetic valve)
    • Scheduled for carotid endarterectomy (randomization is possible 30 days after endarterectomy)
  • CT scan with an intracranial lesion other than brain infarction (space occupying mass, intracranial hemorrhage)
  • Transesophageal echocardiography (TEE) with plaque ≥ 4 mm in thickness distal to the supposed embolized artery (judgement of the investigator).
  • Contraindication to clopidogrel, aspirin, and oral anticoagulants

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Clopidogrel-aspirin
Clopidogrel-aspirin
有源比较器:Warfarin
华法林

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death
大体时间:every 4 months
New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death
every 4 months

次要结果测量

结果测量
措施说明
大体时间
Recurrent brain infarction
大体时间:during the trial
Recurrent brain infarction
during the trial
brain infarction and transient ischemic attack (TIA)
大体时间:during the studing
brain infarction and transient ischemic attack (TIA)
during the studing
new vascular events and revascularization procedure
大体时间:during the trial
new vascular events and revascularization procedure
during the trial
vascular death
大体时间:during the trial
vascular death
during the trial
death from all causes
大体时间:during the trial
death from all causes
during the trial
combination of primary end-point and TIA
大体时间:during the trial
combination of primary end-point and TIA
during the trial
revascularization procedures
大体时间:during the trial
revascularization procedures
during the trial
urgent rehospitalization for ischemic
大体时间:during the trial
urgent rehospitalization for ischemic
during the trial

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Pierre Amarenco, Pr, MD, PhD、Assistance Publique - Hôpitaux de Paris

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2002年2月1日

初级完成 (实际的)

2010年12月1日

研究完成 (实际的)

2012年7月1日

研究注册日期

首次提交

2005年10月6日

首先提交符合 QC 标准的

2005年10月6日

首次发布 (估计)

2005年10月10日

研究记录更新

最后更新发布 (估计)

2012年7月10日

上次提交的符合 QC 标准的更新

2012年7月6日

最后验证

2012年7月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅